- Home
- BIAF vs MRKR Comparison
BIAF vs MRKR Comparison
Compare BIAF & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- MRKR
- Stock Information
- Founded
- BIAF 2014
- MRKR N/A
- Country
- BIAF United States
- MRKR United States
- Employees
- BIAF N/A
- MRKR N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- MRKR Health Care
- Exchange
- BIAF Nasdaq
- MRKR Nasdaq
- Market Cap
- BIAF 13.0M
- MRKR 11.6M
- IPO Year
- BIAF 2022
- MRKR N/A
- Fundamental
- Price
- BIAF $2.49
- MRKR $1.01
- Analyst Decision
- BIAF Hold
- MRKR Strong Buy
- Analyst Count
- BIAF 1
- MRKR 3
- Target Price
- BIAF N/A
- MRKR $13.17
- AVG Volume (30 Days)
- BIAF 3.3M
- MRKR 268.2K
- Earning Date
- BIAF 11-13-2025
- MRKR 11-13-2025
- Dividend Yield
- BIAF N/A
- MRKR N/A
- EPS Growth
- BIAF N/A
- MRKR N/A
- EPS
- BIAF N/A
- MRKR N/A
- Revenue
- BIAF $7,681,059.00
- MRKR $5,388,071.00
- Revenue This Year
- BIAF N/A
- MRKR N/A
- Revenue Next Year
- BIAF $20.04
- MRKR $9.06
- P/E Ratio
- BIAF N/A
- MRKR N/A
- Revenue Growth
- BIAF 4.99
- MRKR 44.55
- 52 Week Low
- BIAF $2.34
- MRKR $0.81
- 52 Week High
- BIAF $46.53
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- BIAF 46.54
- MRKR 50.04
- Support Level
- BIAF $2.43
- MRKR $0.96
- Resistance Level
- BIAF $3.50
- MRKR $1.05
- Average True Range (ATR)
- BIAF 0.29
- MRKR 0.05
- MACD
- BIAF -0.09
- MRKR 0.00
- Stochastic Oscillator
- BIAF 5.69
- MRKR 37.27
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.